Atigotatug/Nivolumab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A fixed-dose combination formulation composed of atigotatug, a human immunoglobulin G1 (IgG1) monoclonal antibody directed against the ganglioside fucosyl-GM1, and nivolumab, a human immunoglobulin G4 (IgG4) monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1), with immune checkpoint inhibitory and antineoplastic activities. Upon administration of atigotatug/nivolumab, atigotatug binds to fucosyl-GM1 on cancer cells and may activate both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against the bound tumor cells. This may inhibit the proliferation of GM1-expressing tumor cells. Nivolumab binds to and blocks the activation of PD-1 by its ligands programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), which is overexpressed on certain cancer cells, and programmed cell death-1 ligand 2 (PD-L2; cluster of differentiation 273; CD273), which is primarily expressed on antigen-presenting cells (APCs). This prevents PD-1-mediated signaling and PD-1-mediated inhibition of the immune response, and results in the activation of T-cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity. Fucosyl-GM1, a sphingolipid monosialoganglioside and tumor associated antigen (TAA), is overexpressed on the surface of many cancer cells while its expression is minimal or non-existent in normal tissues.

**Synonyms:** - Atigotatug and Nivolumab - Atigotatug-Nivolumab - BMS 986489 - BMS-986012 Plus Nivolumab Fixed Dose Combination - BMS-986489 - BMS986489